Details of the Drug Combinations

General Information of This Drug (ID: DM3FXMA)

• Drug Name: Naloxone (DM3FXMA)
• Synonyms: Nalone; Nalossone; Naloxona; Naloxonum; Narcan; Narcanti; Narcon; DBL Naloxone; Nalossone [DCIT]; Naloxone HCl; EN 1530base; DBL Naloxone (TN); L-Naloxone; N-Allylnoroxymorphone; Nalone (TN); Naloxona [INN-Spanish]; Naloxone (INN); Naloxone [INN:BAN]; Naloxonum [INN-Latin]; Narcan (TN); Narcanti (TN); N-Allyl-noroxymorphone; L-N-Allyl-14-hydroxynordihydromorphinone; L-N-Allyl-7,8-dihydro-14-hydroxynormorphinone; N-Allyl-4,5alpha-epoxy-3,14-dihydroxy-6-morphinanon; Morphinan-6-one, 17-allyl-4,5alpha-epoxy-3,14-dihydroxy-(8CI); Morphinan-6-one, 4,5-epoxy-3,14-dihydroxy-17-(2-propenyl)-, (5alpha)-(9CI); (-)-N-allyl-14-hydroxynordihydroxymorphinan-6-one; (-)-Naloxone; (5alpha)-3,14-dihydroxy-17-prop-2-en-1-yl-4,5-epoxymorphinan-6-one; (5alpha)-4,5-Epoxy-3,14-dihydroxy-17-(2-propenyl)morphinan-6-one; 1-N-Allyl-14-hydroxynordihydromorphinone; 1-N-Allyl-7,8-dihydro-14-hydroxynormorphinone; 12-Allyl-7,7a,8,9-tetrahydro-3,7a-dihydroxy-4aH-8,9c-iminoethanophenanthro(4,5-bcd)furanone; 12-Allyl-7,7a,8,9-tetrahydro-3,7a-dihydroxy-4aH-8,9c-iminoethanophenanthro[4,5-bcd]furan-5(6H)-one; 17-Allyl-4,5-alpha-epoxy-3,14-dihydroxymorphinan-6-one; 17-Allyl-4,5alpha-epoxy-3,14-dihydroxymorphinan-6-one; 17-allyl-3,14-dihydroxy-4,5alpha-epoxymorphinan-6-one; 3,14-dihydroxy-17-(prop-2-en-1-yl)-4,5alpha-epoxymorphinan-6-one

Indication

Narcotic depression; ICD 11: 6A7Z; Status: Approved [1]; Pain; ICD 11: MG30-MG3Z; Status: Approved [2]; Pruritus; ICD 11: EC90; Status: Phase 3 [3]; Respiratory depression; ICD 11: MD11.5; Status: Phase 3 [4]; Opioid dependence; ICD 11: 6C43.2Z; Status: Phase 1 [4]

• Therapeutic Class: Antinarcotic Agents
• Drug Type: Small molecular drug

List of Combinatorial Drugs (CBD) Containing This Drug

6 Clinical Trial Drug Combination(s) Consisting of This drug

DrugCom Name	DrugCom ID	Component Drug	Indication	REF
Naloxone + Ramosetron	DC23SSD	Ramosetron	Postoperative Nausea and Vomiting	[5]
Naloxone + Oxycodone	DCGMJ03	Oxycodone	Postoperative Pain	[6]
Naloxone + Clonidine	DCUH0KL	Clonidine	Experimental Pain Perception	[7]
Naloxone + Sulfasalazine	DC54IXR	Sulfasalazine	Intestinal Obstruction	[8]
Naloxone + Flumazenil	DCJ6USG	Flumazenil	Brain Death	[9]
Naloxone + Epinephrine	DCTPGUA	Epinephrine	Diabetes Mellitus	[10]

1 Approved Drug Combination(s) Consisting of This drug

DrugCom Name	DrugCom ID	Component Drug	Indication	REF
Naloxone + Buprenorphine	DCRY2XX	Buprenorphine	Opioid dependence; Major depressive disorder	[11]

References

• [1] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 1668).
• [2] Naloxone FDA Label
• [3] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [4] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [5] ClinicalTrials.gov (NCT02416115) Anti Emetic Efficacy of Combination of Ramosetron and Premixture of Naloxone With Patient-controlled Analgesia
• [6] ClinicalTrials.gov (NCT01109511) A Comparison of Oxycodone/Naloxone and Oxycodone After Laparoscopic Hysterectomy
• [7] ClinicalTrials.gov (NCT01851486) The Relationships Between the Noradrenergic, Opioid and Pain System
• [8] ClinicalTrials.gov (NCT01596764) Effects of Methylnaltrexone in Comparison to Naloxone on Loperamide-induced Delay of the Oro-cecal, Whole-gut and Colon Transit Time.
• [9] ClinicalTrials.gov (NCT03743805) Rapid Reversal of CNS-Depressant Drug Effect Prior to Brain Death Determination
• [10] ClinicalTrials.gov (NCT00678145) Mechanisms of Hypoglycemia Associated Autonomic Failure
• [11] FDA Drug Development and Drug Interactions